Skip to Content

AVEO Pharmaceuticals, Inc. (AVEO)

Securities Class Action

Overview
  • Date:
  • 2/3/2019
  • Status:
  • Closed/Complete

Case Finder

Locate any case using the tools below.

NEW YORK, February 3, 2019 – Bragar Eagel & Squire, P.C. is investigating potential claims against AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO).  Our investigation concerns whether AVEO has violated the federal securities laws and/or engaged in other unlawful business practices.

On January 31, 2019, Boston Business Journal reported that “Aveo revealed that it won’t submit its application for FDA approval due to a recommendation from the agency gather more late-stage testing results.  Specifically, the FDA is asking for additional survival data, echoing concerns that led to the agency’s rejection of the same drug in 2013.”

On this news, AVEO’s share price fell by more than 56%, closing at $0.76 per share on January 31, 2019.

If you purchased or otherwise acquired AVEO shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: